TY - JOUR
T1 - Glucagon-like peptide-1, glucose homeostasis and diabetes.
AU - Holst, Jens Juul
AU - Deacon, Carolyn F
AU - Vilsbøll, Tina
AU - Krarup, Thure
AU - Madsbad, Sten
N1 - Keywords: Diabetes Mellitus; Glucagon-Like Peptide 1; Glucose; Homeostasis; Humans
PY - 2008
Y1 - 2008
N2 - Incretins, enhancers of insulin secretion, are essential for glucose tolerance, and a reduction in their function might contribute to poor beta-cell function in patients with type-2 diabetes mellitus. However, at supraphysiological doses, the incretin glucagon-like peptide-1 (GLP-1) protects pancreatic beta cells, and inhibits glucagon secretion, gastric emptying and food intake, leading to weight loss. GLP-1 mimetics, which are stable-peptide-based activators of the GLP-1 receptor, and incretin enhancers, which inhibit the incretin-degrading enzyme dipeptidyl peptidase-4, have emerged as therapies for type-2 diabetes and have recently reached the market. The pathophysiological basis the clinical use of these therapeutics is reviewed here.
AB - Incretins, enhancers of insulin secretion, are essential for glucose tolerance, and a reduction in their function might contribute to poor beta-cell function in patients with type-2 diabetes mellitus. However, at supraphysiological doses, the incretin glucagon-like peptide-1 (GLP-1) protects pancreatic beta cells, and inhibits glucagon secretion, gastric emptying and food intake, leading to weight loss. GLP-1 mimetics, which are stable-peptide-based activators of the GLP-1 receptor, and incretin enhancers, which inhibit the incretin-degrading enzyme dipeptidyl peptidase-4, have emerged as therapies for type-2 diabetes and have recently reached the market. The pathophysiological basis the clinical use of these therapeutics is reviewed here.
U2 - 10.1016/j.molmed.2008.01.003
DO - 10.1016/j.molmed.2008.01.003
M3 - Journal article
C2 - 18353723
SN - 1471-4914
VL - 14
SP - 161
EP - 168
JO - Trends in Molecular Medicine
JF - Trends in Molecular Medicine
IS - 4
ER -
